Articles from Rivus Pharmaceuticals, Inc.

- Top-line data expected in mid-2027; Actively planning for HU6’s late-stage development in MASH -

Pharmaceutical veteran with extensive late-stage development and commercial experience to lead Rivus as it advances its pipeline of oral medicines that leverage energy expenditure for the treatment of MASH, obesity, and associated cardiometabolic diseases

– Trial met primary endpoint, with statistically significant reductions in liver fat observed in all HU6 treatment groups –

First data from Rivus’ preclinical CMA pipeline showing potential as monotherapy and in combination with GLP-1s